Vimarsana
Biggest News Aggregation in the World

Secondary Levels News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Secondary Levels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Secondary Levels Today - Breaking & Trending Today

Use more location-specific heat indices, Pagasa told - Vimarsana News

Use more location-specific heat indices, Pagasa told

Apparently taking a leaf from his own home city’s practice, Sen. Sherwin Gartchalian is urging the Philippine Atmospheric, Geophysical and Astronomical Services Administration (PAGASA) to come up with more granular and location-specific heat indices to guide schools and local government units. This, he said, will remove the “arbitrariness” in class…

21 graduates from Cebu-based schools top September 2023 teachers' board exams - Vimarsana News

21 graduates from Cebu-based schools top September 2023 teachers' board exams

Discover the top 21 graduates from Cebu-based schools who excelled in the September 2023 Licensure Examination for Professional Teachers (LEPT). From the University of the Philippines (UP)-Cebu to Cebu Normal University (CNU) and more, these top performers achieved remarkable ratings in both elementary and secondary levels. Learn about their inspiring journeys, preparations, and heartfelt advice for aspiring educators. Read on to be inspired by their dedication and success in the teaching profession.

Incyte und MorphoSys melden Eingang der von der Europäischen Kommission erteilten Zulassung für Minjuvi (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von Erwachsenen mit rezidiviertem oder refraktärem diffusem großzelligem... - Vimarsana News

Incyte und MorphoSys melden Eingang der von der Europäischen Kommission erteilten Zulassung für Minjuvi (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von Erwachsenen mit rezidiviertem oder refraktärem diffusem großzelligem...

- Entscheidung der Kommission basiert auf Daten aus der Studie L-MIND zur Prüfung von Minjuvi in Kombination mit Lenalidomid als Behandlung von Patienten mit rezidiviertem oder refraktärem DLBCL -